RxDoctor Payments Data

Vikramaditya Dulam, MD

Cardiovascular Disease · Natchez, MSNPI 1194767806

Payments from drug & device makers

$2,771in general payments, 2019–2025

Across 117 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$503
  • Merck$476
  • Johnson & Johnson$422
  • Boehringer Ingelheim$390
  • AstraZeneca$249
  • Novartis$231
  • plus $499 from 9 others

What the payments were for

  • Food & beverage$2,66496%
  • Education$1074%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,771 in reported general payments places this provider in the 40th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$700,544
Medicare patients
709
Services billed
6,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban171$192,098
EntrestoSacubitril/Valsartan154$184,991
EliquisApixaban100$93,353
BrilintaTicagrelor149$84,308
FarxigaDapagliflozin Propanediol17$27,136
JardianceEmpagliflozin27$26,814
Repatha SureclickEvolocumab29$21,231
Flecainide Acetate281$8,502
Amiodarone Hcl230$3,995
ClopidogrelClopidogrel Bisulfate258$3,198
Metolazone117$3,016
Nebivolol Hcl50$2,677
Digoxin95$2,076
Metoprolol Succinate174$2,033
Potassium Chloride152$1,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$422$192,098171 claims
NovartisEntresto$231$184,991154 claims
AstraZenecaBrilinta, Farxiga$249$111,444166 claims
PfizerEliquis$184$93,353100 claims
Boehringer IngelheimJardiance$390$26,81427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 144 cardiovascular disease providers in Mississippi.

Other cardiovascular disease in Natchez

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →